test

Scott Smith

@Acuta Capital Partners, Llc

Latest period2024 - Q3ReportedManaged Assets$123.464MTotal holdings41
Assets growth rate3.99%Assets growth rate (2-Q avg)-9.44%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Acuta Capital Partners, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 41 positions.

Assets under management

The assets under management (AUM) of Acuta Capital Partners, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 123.464M in assets, with a quarterly growth rate of 3.99% and a 2-quarter average growth rate of -9.44%. The portfolio is managed by Scott Smith, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
SLRNAcelyrin Inc
Recent Activity
New Position
1.46%
$1.795M
364,000 shares@ $4.93 avg price
EWTXEdgewise Therapeutics Inc
Recent Activity
New Position
1.37%
$1.681M
63,000 shares@ $26.69 avg price
DYNDyne Therapeutics Inc
Recent Activity
Decreased -78.25%
1.35%
$1.66M
46,200 shares@ $35.92 avg price
GILDGilead Sciences Inc
Recent Activity
New Position
1.33%
$1.635M
19,500 shares@ $83.84 avg price
RAREUltragenyx Pharmaceutical Inc
Recent Activity
New Position
1.13%
$1.394M
25,100 shares@ $55.55 avg price
TRVITrevi Therapeutics Inc
Recent Activity
Increased 11.74%
0.79%
$970,270
290,500 shares@ $3.34 avg price
UNCYUnicycive Therapeutics Inc
Recent Activity
New Position
0.66%
$807,315
1.979M shares@ $0.41 avg price
LQDALiquidia Corporation
Recent Activity
New Position
0.6%
$735,000
73,500 shares@ $10.0 avg price
VERVVerve Therapeutics Inc
Recent Activity
New Position
0.58%
$707,124
146,100 shares@ $4.84 avg price
GERNGeron Corp
Recent Activity
New Position
0.57%
$703,246
154,900 shares@ $4.54 avg price